Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast AS's purchase of property, plant, equipment for the
three
months ended in Mar. 2026 was $-62 Mil. It means Coloplast AS spent $62 Mil on purchasing property, plant, equipment.
Coloplast AS's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Mar. 2026 was $-237Mil.
Compared with last quarter ($-58 Mil in Dec. 2025 ), Coloplast AS spent more money on purchasing property, plant, equipment in Mar. 2026 ($-62 Mil).
Coloplast AS Purchase Of Property, Plant, Equipment Related Terms
Coloplast AS Purchase Of Property, Plant, Equipment Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Purchase Of Property, Plant, Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS Purchase Of Property, Plant, Equipment Chart
Coloplast AS Purchase Of Property, Plant, Equipment Calculation
The amount used to purchase PPE.
Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-237 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Purchase Of Property, Plant, Equipment of $-237 Mil mean?
Coloplast AS (CLPBY) has a Purchase Of Property, Plant, Equipment of $-237 Mil as of Mar. 2026. Purchase of PP&E is the total purchase of property, plant and equipment. View historical data for Coloplast AS and its competitors.
Is Coloplast AS's Purchase Of Property, Plant, Equipment too high?
Coloplast AS's current Purchase Of Property, Plant, Equipment is $-237 Mil. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Purchase Of Property, Plant, Equipment compare to ISRG and BDX?
Coloplast AS's Purchase Of Property, Plant, Equipment of $-237 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Purchase Of Property, Plant, Equipment for a Medical Devices & Instruments company?
A good Purchase Of Property, Plant, Equipment depends on the Medical Devices & Instruments industry context. However, Purchase Of Property, Plant, Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Purchase Of Property, Plant, Equipment mean?
A high Purchase Of Property, Plant, Equipment can signal that a stock is expensive relative to its fundamentals. Purchase of PP&E is the total purchase of property, plant and equipment. View historical data for Coloplast AS and its competitors. Coloplast AS's current Purchase Of Property, Plant, Equipment is $-237 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.74 — trading 48.4% below its estimated fair value. The current Purchase Of Property, Plant, Equipment is $-237 Mil. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Purchase Of Property, Plant, Equipment calculated?
Purchase Of Property, Plant, Equipment is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Purchase Of Property, Plant, Equipment is $-237 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.74 is trading 48.4% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Purchase Of Property, Plant, Equipment: $-237 Mil
GF Value™: $13.05 vs. price of $6.74 (48.4% below fair value)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Purchase Of Property, Plant, Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
